How to Make a Clinical Trial Results Presentation

Presenting clinical trial results is a high-stakes communication task. Your audience — whether a Data Safety Monitoring Board, a scientific conference, a regulatory agency, or an investor group — needs to understand what you found, how confident you are in the finding, and what it means for patients or practice. The structure of your presentation either supports or undermines that understanding.

Know Your Audience Before You Build

A clinical trial results presentation for a Phase III NDA submission to the FDA looks nothing like a conference keynote or an investor update. Tailor accordingly:

• Regulatory audience (FDA, EMA): Exhaustive protocol adherence, ITT and PP populations, full safety tables, adverse event breakdown by severity grade
• Scientific/clinical audience: Primary endpoint results, pre-specified subgroups, comparison to existing standard of care, clinical meaningfulness
• Investor/business audience: Top-line efficacy, safety profile summary, market differentiation, path to approval
• DSMB/IRB: Safety signals, protocol deviations, interim analysis findings, stopping rules assessment

Standard Slide Structure

Slide 1 — Study Title and Identifier

Full study name, NCT number, phase, sponsor. If presenting at a conference, include the abstract number.

Slide 2 — Background and Rationale

Brief. Two to three slides maximum. The clinical unmet need, the mechanism of action or intervention rationale, and the primary hypothesis. Audience members who aren't deep in your therapeutic area need this context.

Slide 3 — Study Design Overview

A schema diagram is more efficient than prose here. Show: patient population → randomization → treatment arms → primary endpoint assessment → follow-up period. Include the sample size and key statistical assumptions (alpha, power, expected effect size).

Slides 4–5 — Patient Population (CONSORT Flow)

Use the CONSORT diagram for randomized trials. Show screening, enrollment, randomization, and analysis populations. Include the number lost to follow-up and reasons for discontinuation. Demographic and baseline characteristic tables belong here.

Slides 6–9 — Primary Endpoint Results

The core of the presentation. For each primary endpoint:

• State the endpoint definition precisely
• Show the result for each arm with confidence intervals
• Include the p-value and pre-specified alpha threshold
• Display Kaplan-Meier curves for time-to-event endpoints
• Show the primary analysis model and any covariate adjustments

For the primary efficacy endpoint, a single clean chart with the key number prominently labeled is more persuasive than a crowded table.

Slides 10–12 — Secondary and Exploratory Endpoints

Present pre-specified secondary endpoints with appropriate multiplicity adjustments. Clearly label exploratory analyses as hypothesis-generating, not confirmatory. Forest plots work well for subgroup analyses — always include the test for interaction.

Slides 13–15 — Safety Results

Organize by:

1. Treatment-emergent adverse events (any grade, ≥5% incidence by arm)
2. Grade 3/4 adverse events
3. Serious adverse events
4. Deaths and cause
5. Discontinuations due to adverse events

Use tables rather than charts for safety data — precision matters more than visual appeal here. Clinicians need the exact numbers.

Slide 16 — Subgroup Analyses

Forest plot with pre-specified subgroups. Include total N for each subgroup. Resist interpreting exploratory subgroups as definitive findings.

Slide 17 — Clinical Interpretation

Translate statistical results into clinical meaning. What does a 3.2-month improvement in PFS mean for a patient with this diagnosis? How does your adverse event rate compare to current standard of care? This is where the medical case is made.

Slide 18 — Limitations

All trials have limitations. Address them directly:

• Open-label vs. blinded assessment
• Generalizability of the population
• Follow-up duration relative to typical disease course
• Any protocol amendments and their impact

Addressing limitations proactively is more credible than waiting for the question period.

Slide 19 — Conclusions

Three to five bullet points. Lead with the primary finding and its statistical confidence. Follow with safety summary. End with the implication for clinical practice or next steps.

Data Visualization Standards

Confidence intervals are mandatory for all efficacy estimates. A p-value without a CI is insufficient for clinical decision-making.

Kaplan-Meier curves should include the number at risk below the x-axis. They should not be cut off before the event rate drops to a meaningful threshold.

Bar charts with error bars should specify what the error bars represent (SD, SE, or 95% CI). This distinction matters enormously and is frequently omitted.

Tables should use a consistent decimal precision column by column. Mixing two and three decimal places within a column is a quality control failure.

Regulatory-Specific Considerations

If this presentation accompanies an NDA or BLA submission, all presented data must be traceable to the clinical study report. Slide numbers referenced in the submission package should correspond to the data tables in the appendices. Discrepancies between slides and source data are a serious credibility risk.

Building the Deck

Use a consistent, clean template throughout. Clinical trial presentations are evaluated on scientific rigor first and visual design second, but poor visual design creates cognitive friction that works against you. Slide-deck.io provides clean templates that don't distract from the data — use them as a foundation, then build your figures in your preferred statistical software and import at high resolution.

Keep the deck to 20–25 slides for a 20-minute conference presentation. Regulatory submissions may require more, but the core narrative should be communicable in that window.